ANGPTL3 and fatty liver disease: Since studies have shown that obese mouse models treated with an ANGPTL3 antagonist peptide showed a marked reversal of diet-induced obesity and hepatic steatosis [28], the lack of improvement in glycemia and steatosis in the previous study has been attributed to underpowered effects due to its small sample size [6].